YD Bio (YDES) Other Non-Current Liabilities (2024 - 2025)
YD Bio (YDES) posted quarterly Other Non-Current Liabilities of $14991.5 billion for Q4 2025, up 397235.86% year-over-year from N/an in Q4 2024, and up 397235.86% quarter-over-quarter from $3.8 billion in Q4 2024.
YD Bio (YDES) Other Non-Current Liabilities (2024 - 2025) Analysis & Trends
YD Bio (YDES) has reported Other Non-Current Liabilities for 2 consecutive years, with $14991.5 billion the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Non-Current Liabilities rose 397235.86% year-over-year to $14991.5 billion; the TTM figure through Dec 2025 stood at $14991.5 billion (up 397235.86% YoY), while the FY2025 annual figure was $14991.5 billion, up 397235.86% from the prior year.
- Other Non-Current Liabilities rose to $14991.5 billion in Q4 2025 per YDES's latest filing, from $3.8 billion in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $14991.5 billion in Q4 2025 and bottomed at $3.8 billion in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | YD Bio | 314.91 Mn | 308.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 14,991.48 Bn |
| Dec 31, 2024 | 3.77 Bn |